Moderna Takes The Lead With Plan To Tackle New COVID-19 Variants
New Tweaked Booster To Enter Phase I Study
Moderna has unveiled plans to develop a new booster vaccine, tweaked to meet the threat posed by the South African strain.
You may also be interested in...
US FDA v. COVID Mutants: Multi-Factorial Assessments Will Determine When Product EUAs Need To Change
Acting Commissioner Janet Woodcock offers hints as to the content of upcoming guidance on how emerging virus variants may impact vaccine and therapeutic development. US may need multivalent vaccine and multiple boosters.
Pfizer said it expects its COVID-19 vaccine to generate $15bn in 2021, but the forecast appears to be an underestimation as it includes only contracted doses.
While vaccine has efficacy rate of 74% in the US, it completely prevented hospitalizations and deaths, which Fauci says is the most important result from a public health perspective. Vaccine findings cannot be compared given emergence of variants since Moderna and Pfizer conducted their studies, Janssen global head of R&D says.